Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women

Journal of the International Association of Providers of AIDS Care

Volumn 14, Issue 5, 2015, Pages 415-422

  Lemonovich, Tracy L ^a   Watkins, Richard R ^b   Morrison, Charles S ^c   Kwok, Cynthia ^c   Chipato, Tsungai ^d   Musoke, Robert ^e   Arts, Eric J ^a   Nankya, Immaculate ^a   Salata, Robert A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d UNIV OF ZIMBABWE MEDICAL SCHOOL   (Zimbabwe)

^e MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

acute HIV infection; clinical manifestations; HIV 1 subtype; STDs; women

Indexed keywords

DNA POLYMERASE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS DNA;

ABDOMINAL PAIN; ACUTE HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; AFRICAN; ARTICLE; CANDIDIASIS; CERVICAL FRIABILITY; CHLAMYDIASIS; CLINICAL FEATURE; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; EARLY HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENITAL ULCER; GONORRHEA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INGUINAL ADENOPATHY; LONGITUDINAL STUDY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; NAUSEA; NIGHT SWEAT; PAIN; PHYSICAL DISEASE BY BODY FUNCTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; RASH; SEROLOGY; SYMPTOM ASSESSMENT; TRICHOMONIASIS; UGANDA; UTERINE CERVIX DISEASE; VAGINA DISCHARGE; VAGINA EPITHELIUM; VAGINITIS; WEIGHT REDUCTION; ZIMBABWE; ZIMBABWEAN; ACUTE DISEASE; ADOLESCENT; ADULT; BLOOD; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY; VIROLOGY; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; FEMALE; FEVER; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; UGANDA; WEIGHT LOSS; YOUNG ADULT; ZIMBABWE;

EID: 84941954757     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957413504827     Document Type: Article

References (30)

1. Simon F, Mauclere P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med. 2002; 4 (9): 1032-1037.
2. Janssens W, Buve A, Nkengasong JN,. The puzzle of HIV-1 subtypes in Africa. AIDS. 1997; 11 (6): 705-712.
3. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis. 2006; 42 (6): 843-852.
4. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM,. The challenge of HIV-1 subtype diversity. N Eng J Med. 2008; 358 (15): 1590-1602.
5. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008; 197 (5): 707-713.
6. Machekano R, Bassett M, McFarland W, Katzenstein D.; Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe. HIV Clin Trials. 2002; 3 (2): 148-154.
7. Kanki PJ, Hamel DJ, Sankale JL, et al. HIV-1 subtypes differ in disease progression. J Infect Dis. 1999; 179 (1): 68-73.
8. Nelson JR, John GC, Carr JC, et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol. 1999; 73 (5): 4393-4403.
9. John-Stewart GC, Nduati RW, Rousseau CM, et al. Subtype C is associated with increased vaginal shedding of HIV-1. J Infect Dis. 2005; 192 (3): 492-496.
10. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J,. Similar rates of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS. 1999; 13 (8): 901-907.
11. Galai N, Kalinkovich A, Burstein R, Vlahov D, Bentwich Z,. HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel. Lancet. 1997; 349 (9046): 180-181.
12. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 2009; 48 (9): 1296-1305.
13. Schacker T, Collier AC, Hughes J, Shea T, Corey L,. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996; 125 (4): 257-264.
14. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis. 2006; 42 (9): 1333-1339.
15. Richey LE, Halperin J,. Acute human immunodeficiency virus infection. Am J Med Sci. 2013; 345 (2): 136-142.
16. Kahn JA, Walker BR,. Acute human immunodeficiency type 1 infection. N Engl J Med. 1998; 339: 133-139.
17. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005; 191 (9): 1403-1409.
18. Morrison CS, Richardson BA, Mmiro F, et al. for the Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. Hormone contraception and the risk of HIV acquisition. AIDS. 2007; 21 (1): 85-95.
19. Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010; 24 (4): 573-582.
20. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with nonsubtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2004; 20 (4): 355-364.
21. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007; 195 (8): 1177-1180.
22. Morrison CS, Chen PL, Nankya I, et al. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Aquir Immune Defic Syndr. 2011; 57 (2): 157-164.
23. Easterbrook PJ, Smith M, Mullen J,. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc. 2010; 13: 4.
24. Lutalo T, Gray RH, Wawer M, et al. Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda. AIDS. 2007; 21 (suppl 6): S15-S19.
25. Morgan D, Mahe C, Whitworth J,. Absence of a recognizable seroconversion illness in Africans infected with HIV-1. AIDS. 2001; 15 (12): 1575-1576.
26. Senkaali D, Muwonge R, Morgan D, Yirrell D, Wittworth J, Kaleebu P,. The relationship between HIV type 1 disease progression and V3 serotype in a rural Ugandan cohort. AIDS Res Hum Retroviruses. 2004; 20 (9): 932-937.
27. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1 positive persons in Uganda. J Infect Dis. 2002; 185 (9): 1244-1250.
28. Lavreys L, Thompson ML, Martin HL Jr, et al. Primary human immunodeficiency virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000; 30 (3): 486-490.
29. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Milawi: a modeling study. Lancet. 2011; 378 (9787): 256-268.
30. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early anti-retroviral therapy. N Engl J Med. 2011; 365 (6): 493-505.